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===========

The world is battling an immense threat from novel corona virus disease 2019 (COVID-19). As of 28 April 2020, more than 3.1 million confirmed COVID-19 cases had been reported from over 150 countries, among whom over 220,000 had died \[[@ref1]\]. Most COVID-19-related deaths have been attributed to multiple organ failure in older or comorbid individuals \[[@ref2]\].

A recent meta-analysis estimated that 2% of patients with COVID-19 had cancer \[[@ref3]\]. However, the analysis included only data from China and did not evaluate the association of cancer with severe COVID-19 disease. Cancer patients may be more susceptible to COVID-19 than healthy individuals due to their high immunosuppressive burden caused by the cancer and anticancer treatments \[[@ref4]\]. Improved understanding of the burden of cancer in COVID-19 patients may help to guide clinical management. Hence, in this study, we aimed to estimate the prevalence of cancer among COVID-19-infected patients as well as ascertain the association between cancer and disease severity.

Methods
=======

A systematic review was performed in accordance with the recommendations outlined in the PRISMA statement \[[@ref5]\] and the Cochrane Handbook \[[@ref6]\]. We searched MEDLINE, EMBASE and ScienceDirect using the terms 'comorbidities' or 'clinical characteristics' or 'epidemiological' and 'COVID-19' or 'Coronavirus' or '2019-nCoV' or 'SARS-CoV-2' or '2019 novel coronavirus' ([Supplemental Table S1](#tableS1){ref-type="table"}). The search was last updated on April 28, 2020. Further searches were also performed via the websites of the World Health Organization (WHO) and key public health institutions in some of the most affected countries ([Supplementary Table S2](#tableS2){ref-type="table"}) \[[@ref1]\]. The reference lists of identified studies were also screened for additional papers. Two reviewers (O.O and R.O) performed article screening and any disagreements were resolved via consensus. Severe disease was considered to encompass cases resulting in death \[[@ref7]\] or as defined by the study authors \[[@ref7]\]. The quality of individual studies was evaluated using the Newcastle--Ottawa Scale (NOS) for non-randomized studies \[[@ref8]\]. For each study, two reviewers (R.O and O.O) independently collected data, including author details, country (region), mean age, proportion of females, and data on prevalence and disease severity. We excluded studies based on family clusters, those focusing solely on deceased individuals and case series involving \<10 patients or only children. Moreover, reviews, commentaries and editorials were excluded. Furthermore, because a national-based study in China was published with data up to February 11, 2020, we excluded all sub-national studies in China that recruited only patients up until that date. However, if a study based in China recruited patients beyond this date, they were included. Also, if studies from the same region or hospital recruiting patients over the period were present, we selected the report with the larger sample size or more detailed data.

Meta-analysis of prevalence was performed using Freeman--Tukey double arcsine transformation to adjust for variance instability \[[@ref9]\]. Owing to anticipated between-study heterogeneity, random-effect model was used \[[@ref6]\]. Furthermore, pooled risk ratios (RRs) and corresponding 95% confidence intervals (CIs) were derived to characterise the association between cancer and the occurrence of severe disease. Between-study heterogeneity was quantified using the *I*^2^ statistic \[[@ref5]\]. A leave-one-out sensitivity analyses assessed the stability of pooled estimates. We applied meta-regression to determine whether the pooled prevalence was moderated by the age of study participants, gender distribution or location of the study (in/outside of China). All analyses were conducted using Stata SE software version 16 (StataCorp, TX, USA). A two-tailed *p*-value of \<0.05 was considered as significant.

Results
=======

The electronic searches retrieved 2,410 citations. Following removal of duplicates and screening of titles and abstracts, 94 articles were selected for full text evaluation. Twenty articles were retained after full-text assessment ([Figure 1](#figure1){ref-type="fig"}) \[[@ref10]--[@ref29]\]. The included studies were from China (*n* = 10), the United Kingdom (*n* = 2), South Korea (*n* = 1), the United States (*n* = 2), Italy (*n* = 1), Singapore (*n* = 1), India (*n* = 1), France (*n* = 1) and Thailand (*n* = 1). The studies involved a total of 32,404 patients. The mean age ranged from 40.3 to 75.0 years and 18.0% to 67.1% of the patients were females ([Table 1](#table1){ref-type="table"}).

Across the studies, the reported prevalence of cancer ranged from 0% to 21.0%. The pooled prevalence was 3.5% (95% CI 1.7 to 5.8%, *I*^2^ = 97.4%) ([Figure 2](#figure2){ref-type="fig"}). A leave-one-out sensitivity analysis did not change the results (point estimate ranged from 3% to 4%). There was no significant moderation of the pooled prevalence by the participants' mean age (coefficient = 0.0034, *p* = 0.247), proportion of females (coefficient = 0.0006, *p* = 0.557) or being conducted in/outside of China (coefficient = −0.009, *p* = 0.795). Across six studies involving 22,046 patients, those with cancer were more likely to experience severe disease compared to patients without cancer (pooled risk ratio (RR~pooled~) 1.76, 95% CI 1.39 to 2.23, *I*^2^ = 20.9%) ([Figure 3](#figure3){ref-type="fig"}). A leave-one-out analyses did not change the results (the estimates ranged from RR~pooled~ 1.66 (95% CI 1.27 to 2.17) to 1.82 (95% CI 1.26 to 2.64)).

Discussion
==========

The results of our meta-analysis suggest a low prevalence of cancer among COVID-19 patients. However, patients with cancer are 76% more likely to experience severe disease compared to those without cancer. This finding is consistent with a recent study which reported that the fatality of cancer patients infected with the Middle East respiratory syndrome (MERS)-CoV in 2012 was significantly higher compared to patients without cancers \[[@ref31]\]. The greater likelihood of severe COVID-19 in patients with cancer may reflect their increased vulnerability to developing complications of respiratory viruses \[[@ref32]\]. Moreover, many oncology patients often have additional risk factors for severe COVID-19, such as advanced age and presence of other comorbidities \[[@ref32]\].

Our study highlights the need to implement extra precautionary measures (including an awareness campaign) to ensure that patients with cancer are not exposed to the virus during the current outbreak and future outbreaks. The development of a COVID-19 vaccine or treatment modality may also be useful towards reducing the risk of this vulnerable population. Furthermore, it is imperative that during the current COVID-19 outbreak, measures are implemented to minimise interruptions in the provision of essential medical services to cancer patients.

Of note, as expected given the observational nature of the data, there was evidence of high statistical heterogeneity in the pooled prevalence of cancer. This does not necessarily invalidate the findings. Further assessment revealed that the heterogeneity was not entirely explained by differences in age or gender distribution among study population. Also, while the included studies originated from a few countries, around half were conducted in China which may affect the generalisability of our findings. Hence, further analysis would be necessary as the COVID-19 pandemic evolves and data from other regions become available.

Conclusion
==========

Our findings suggest that COVID-19 patients with cancer are more likely to experience severe disease than those without cancer. This emphasises the need to adopt additional precautionary measures to ensure that these vulnerable patients are not exposed to the virus, and if they become infected, extra attention should be provided to minimise their risk of adverse outcomes.
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###### Search strategy.

  --------------------------------------------------
  1 COVID-19.mp.\
  2 COVID-19.m_titl.\
  3 2019 novel coronavirus.mp.\
  4 2019 novel coronavirus.m_titl.\
  5 2019-nCoV.mp.\
  6 2019-nCoV.m_titl.\
  7 SARS-CoV-2.m_titl.\
  8 SARS-CoV-2.m_titl.\
  9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8\
  10 comorbidities.mp. or Comorbidity/\
  11 comorbidity.mp.\
  12 clinical characteristics.mp.\
  13 clinical characteristics.m_titl.\
  14 epidemiological.mp.\
  15 epidemiolog\*.mp. or Epidemiology/\
  16 epidemiological.m_titl.\
  17 epidemiological.mp.\
  18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17\
  19 9 and 18

  --------------------------------------------------

###### Institutional websites of some of the countries searched.

  Country           Institution                                                       Website
  ----------------- ----------------------------------------------------------------- ---------------------------------------------------------------------
  Global            World Health Organization                                         <https://www.who.int/>
  USA               Centers for Disease Control and Prevention                        <https://www.cdc.gov/>
  China             Chinese Centre for Disease Control and Prevention                 <http://www.chinacdc.cn/en/>
  Spain             National Centre of Epidemiology, Institute of Health Carlos III   <https://www.isciii.es/Paginas/Inicio.aspx>
  Germany           Robert Koch Institute (RKI)                                       <https://www.rki.de/EN/Home/homepage_node.html>
  France            Santé Publique France                                             <https://www.santepubliquefrance.fr/>
  Iran              Ministry of Health and Medical Education                          <http://www.behdasht.gov.ir/>
  UK                Public Health England                                             <https://www.gov.uk/government/organisations/public-health-england>
  Switzerland       Federal Office of Public Health                                   <https://www.bag.admin.ch/bag/en/home.html>
  The Netherlands   National Institute of Public Health and the Environment           <https://www.rivm.nl/en>
  Canada            Public Health Agency of Canada                                    <https://www.canada.ca/en/public-health.html>
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###### Characteristics of included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study No.   Author details\*\*                                                                                                                                  Country\                   Hospital                                                                                                                           Last follow up      Sample size   Mean age   \%\      No. (%) with\   No. (%) severe disease^a^   
                                                                                                                                                                  (location)                                                                                                                                                                                                 Female   cancer                                      
  ----------- --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------- ---------- -------- --------------- --------------------------- --------------
  1\.         COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention \[[@ref10]\]   South Korea                Korea Centers for Disease Control and Prevention                                                                                   February 14, 2020   28            42.6       46.4     1 (3.6)         \-                          \-

  2\.         ICNARC \[[@ref11]\]                                                                                                                                 United\                    England, Wales and Northern Ireland critical care units                                                                            March 26, 2020      775^a^        60.2       29.1     12 (1.2)        \-                          \-
                                                                                                                                                                  Kingdom                                                                                                                                                                                                                                                         

  3\.         Wu *et al* \[[@ref12]\]                                                                                                                             China (Jiangsu)            3 grade IIIA hospitals                                                                                                             February 14, 2020   80            46.1       51.3     1 (1.3)         \-                          \-

  4\.         The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team \[[@ref13]\]                                                                   China                      Nationwide                                                                                                                         February 11, 2020   20982^b^      \-         48.6     107 (0.5)       6 (5.6)                     400 (1.9)

  5\.         Zhu *et al* \[[@ref14]\]                                                                                                                            China (Outside of Hubei)   Anhui Province ED                                                                                                                  February 20, 2020   32            46.0       53.0     2 (6.3)         \-                          \-

  6\.         Sun *et al* \[[@ref15]\]                                                                                                                            Singapore                  National\                                                                                                                          February 16, 2020   54            42.0       46.3     0 (0.0)         \-                          \-
                                                                                                                                                                                             Centre for Infectious Diseases                                                                                                                                                                                                       

  7\.         Chen *et al* \[[@ref16]\]                                                                                                                           China (Wuhan)              Tongji Hospital                                                                                                                    February 28, 2020   274           62.0       38.0     7 (3.0)         5 (71.4)                    108 (40.4)

  8\.         Guo *et al* \[[@ref17]\]                                                                                                                            China (Wuhan)              No. 7 Hospital of Wuhan                                                                                                            February 23, 2020   187           58.5       51.3     13 (7.0)        \-                          \-

  9\.         McMichael *et al* \[[@ref18]\]                                                                                                                      US (Washington)            skilled nursing facility in King County                                                                                            March 18, 2020      167           72.0       67.1     15 (9.0)        \-                          \-

  10\.        Gupta *et al* \[[@ref19]\]                                                                                                                          India (New Delhi)          Sarfdarjung hospital                                                                                                               March 19, 2020      21            40.3       33.3     0 (0.0)         \-                          \-

  11\.        Klopfenstein *et al* \[[@ref20]\]                                                                                                                   France                     NFC hospital                                                                                                                       March 17, 2020      54            47.0       67.0     2 (4.0)         \-                          \-

  12\.        Richardson *et al* \[[@ref21]\]                                                                                                                     US (New York)              Northwell Health hospitals                                                                                                         April 4, 2020       5700          63.0       39.7     320 (6.0)       \-                          \-

  13\.        Pan *et al* \[[@ref22]\]                                                                                                                            China (Hubei)              Wuhan Hanan Hospital, Wuhan Union Hospital, and Huanggang Central Hospital                                                         March 18, 2020      204\          52.9       52.5     13 (6.37)       4 (50.0)^c^                 33 (34.7)^c^
                                                                                                                                                                                                                                                                                                                                                    (digestive\                                                                   
                                                                                                                                                                                                                                                                                                                                                    =103)                                                                         

  14\.        Pongpirul *et al* \[[@ref23]\]                                                                                                                      Thailand                   Bamrasnaradura Infectious Diseases Institute                                                                                       January 31, 2020    11            61.0       45.5     0 (0)           \-                          \-

  15\.        Feng *et al* \[[@ref24]\]                                                                                                                           China\                     Jinyintan Hospital in Wuhan, Shanghai Public Health Clinical Center in Shanghai and Tongling People's Hospital in Anhui Province   February 15, 2020   476           53.0       43.1     12 (2.5)        7 (58.3)                    117 (25.2)
                                                                                                                                                                  (Multicentre)                                                                                                                                                                                                                                                   

  16\.        Yu *et al* \[[@ref5]\]                                                                                                                              China (Wuhan)              Zhongnan Hospital of Wuhan University                                                                                              February 17, 2020   1524          \-         \-       12 (0.79)       \-                          \-

  17\.        Grasselli *et al* \[[@ref26]\]                                                                                                                      Italy (Lombardy)           72 hospitals                                                                                                                       March 18, 2020      1591^a^       63.0       18.0     81 (8.0)        \-                          \-

  18\.        Wang et al \[[@ref27]\]                                                                                                                             China (Wuhan)              Renmin Hospital of Wuhan University                                                                                                February 13, 2020   116           54         42.2     12 (10.3)       11 (91.6)                   58/104

  19\.        Chu *et al* \[[@ref28]\]                                                                                                                            China (Wenzhou city)       First Affiliated Hospital of Zhejiang University                                                                                   February 23, 2020   33^a^         65.2       33.3     1 (3.0)         \-                          \-

  20\.        Tomlins *et al* \[[@ref29]\]                                                                                                                        UK (England)               North Bristol NHS Trust                                                                                                            March 30, 2020      95            75.0       37.0     20 (21)         3 (15.0)                    17 (22.7)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
